<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:53:27Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10698219" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10698219</identifier>
        <datestamp>2023-12-07</datestamp>
        <setSpec>diacare</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id>
              <journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id>
              <journal-id journal-id-type="publisher-id">diabetes care</journal-id>
              <journal-title-group>
                <journal-title>Diabetes Care</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0149-5992</issn>
              <issn pub-type="epub">1935-5548</issn>
              <publisher>
                <publisher-name>American Diabetes Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10698219</article-id>
              <article-id pub-id-type="pmcid">PMC10698219</article-id>
              <article-id pub-id-type="pmc-uid">10698219</article-id>
              <article-id pub-id-type="pmid">37824793</article-id>
              <article-id pub-id-type="pmid">37824793</article-id>
              <article-id pub-id-type="publisher-id">231135</article-id>
              <article-id pub-id-type="doi">10.2337/dc23-1135</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Małecki</surname>
                    <given-names>Maciej T.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Batterham</surname>
                    <given-names>Rachel L.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sattar</surname>
                    <given-names>Naveed</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Levine</surname>
                    <given-names>Joshua A.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rodríguez</surname>
                    <given-names>Ángel</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bergman</surname>
                    <given-names>Brandon K.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Hui</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ghimpeteanu</surname>
                    <given-names>Gabriela</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0824-0207</contrib-id>
                  <name>
                    <surname>Lee</surname>
                    <given-names>Clare J.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Department of Metabolic Diseases, Jagiellonian University Medical College, Kraków, Poland</aff>
              <aff id="aff2"><label>2</label>University College London, London, U.K.</aff>
              <aff id="aff3"><label>3</label>Eli Lilly and Company, Basingstoke, U.K.</aff>
              <aff id="aff4"><label>4</label>British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, U.K.</aff>
              <aff id="aff5"><label>5</label>Eli Lilly and Company, Indianapolis, IN</aff>
              <aff id="aff6"><label>6</label>Lilly Spain, Alcobendas, Madrid, Spain</aff>
              <aff id="aff7"><label>7</label>TechData Service Company, King of Prussia, PA</aff>
              <aff id="aff8"><label>8</label>Eli Lilly Romania, Bucharest, Romania</aff>
              <author-notes>
                <corresp id="cor1">Corresponding author: Clare J. Lee, <email>clare.lee@lilly.com</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub" iso-8601-date="2023-12-01">
                <month>12</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2023-10-12">
                <day>12</day>
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>12</day>
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>46</volume>
              <issue>12</issue>
              <fpage>2292</fpage>
              <lpage>2299</lpage>
              <history>
                <date date-type="received" iso-8601-date="2023-06-20">
                  <day>20</day>
                  <month>6</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted" iso-8601-date="2023-09-28">
                  <day>28</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 by the American Diabetes Association</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license>
                  <ali:license_ref start_date="2023-10-12">https://www.diabetesjournals.org/journals/pages/license</ali:license_ref>
                  <license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <ext-link ext-link-type="uri" xlink:href="https://www.diabetesjournals.org/journals/pages/license">https://www.diabetesjournals.org/journals/pages/license</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="dc231135.pdf"/>
              <abstract>
                <sec id="s1">
                  <title>OBJECTIVE</title>
                  <p>To identify predictors of body weight (BW) reduction of ≥15% with tirzepatide treatment and to describe associated clinical parameters of participants with type 2 diabetes (T2D) who achieved different categorical measures of BW reduction (&lt;5%, ≥5 to &lt;10%, ≥10 to &lt;15%, and ≥15%) across four studies from the phase 3 SURPASS clinical trial program for T2D.</p>
                </sec>
                <sec id="s2">
                  <title>RESEARCH DESIGN AND METHODS</title>
                  <p>The multivariate model for predictor of a BW reduction of ≥15% included age, sex, race, BW, HbA<sub>1c</sub>, tirzepatide dose and baseline metformin use, fasting serum glucose, and non-HDL cholesterol. Baseline characteristics and change from baseline to week 40/42 for efficacy parameters were described and analyzed in treatment-adherent participants (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (<italic toggle="yes">N</italic> = 3,188).</p>
                </sec>
                <sec id="s3">
                  <title>RESULTS</title>
                  <p>Factors significantly associated with achieving a BW reduction of ≥15% with tirzepatide were higher tirzepatide doses, female sex, White or Asian race, younger age, metformin background therapy, and lower HbA<sub>1c</sub>, fasting serum glucose, and non-HDL cholesterol at baseline. With higher categorical BW reduction, there were greater reductions in HbA<sub>1c</sub>, triglycerides, ALT, waist circumference, and blood pressure.</p>
                </sec>
                <sec id="s4">
                  <title>CONCLUSIONS</title>
                  <p>Baseline factors associated with a higher likelihood of achieving a BW reduction of ≥15% with tirzepatide were higher tirzepatide doses, female sex, White or Asian race, younger age, metformin background therapy, better glycemic status, and lower non-HDL cholesterol. With greater BW reduction, participants with T2D achieved larger improvements in glycemia and cardiometabolic risk parameters. These findings help inform which people with T2D are most likely to achieve greater BW reduction with improved cardiometabolic risk factors with tirzepatide.</p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical">
                <title>Graphical Abstract</title>
                <p>
                  <fig position="float" id="FGA">
                    <graphic xlink:href="dc231135F0GA" position="float"/>
                  </fig>
                </p>
              </abstract>
              <funding-group>
                <award-group id="sp1">
                  <funding-source>
                    <institution-wrap>
                      <institution>Eli Lilly and Company</institution>
                      <institution-id institution-id-type="DOI">10.13039/100004312</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s6">
              <title>Introduction</title>
              <p>Obesity is a complex, chronic, progressive disease associated with numerous life-limiting complications, including type 2 diabetes (T2D) and cardiovascular diseases (<xref rid="B1" ref-type="bibr">1</xref>). A more robust body weight (BW) reduction beyond the widely accepted goal of ≥5% has been suggested to be necessary to prevent or delay complications related to T2D and obesity. For example, a BW reduction of ≥10% has been shown to be disease modifying, potentially leading to T2D remission (<xref rid="B2" ref-type="bibr">2</xref>). The current international guidelines suggest that weight loss of 5–15% should be a primary target of diabetes management for many people living with T2D (<xref rid="B3" ref-type="bibr">3</xref>). Lifestyle intervention alone, however, may not be sufficient to achieve and sustain (at least beyond the first year) a 10–15% BW reduction needed to achieve and sustain these health goals.</p>
              <p>Tirzepatide is a first-in-class once weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of people with T2D and under investigation for long-term weight management (<xref rid="B4" ref-type="bibr">4</xref>). In the phase 3 SURPASS clinical trial program for T2D, in addition to substantial improvements in glycemic control, treatment with tirzepatide at doses of 5 mg, 10 mg, and 15 mg resulted in greater weight reductions compared with placebo or active comparators in people with T2D on various background medications across the diabetes continuum (<xref rid="B5" ref-type="bibr">5</xref>–<xref rid="B9" ref-type="bibr">9</xref>). Notably, weight reduction did not plateau in any of the three tirzepatide treatment groups by the end of the treatment periods of 40 and 52 weeks.</p>
              <p>The purpose of this post hoc analysis was to identify predictors of a BW reduction of ≥15% with tirzepatide treatment (5 mg, 10 mg, or 15 mg) and to describe baseline characteristics and changes in cardiometabolic risk factors, such as lipids, blood pressure, and glycemia, of tirzepatide-treated participants who achieved different categorical measures of BW reduction (&lt;5%, ≥5 to &lt;10%, ≥10 to &lt;15%, and ≥15%) across four studies from the phase 3 SURPASS clinical trial program for T2D.</p>
            </sec>
            <sec id="s7">
              <title>Research Design and Methods</title>
              <sec id="s8">
                <title>Design of the SURPASS Clinical Trial Program</title>
                <p>The study design, full inclusion and exclusion criteria, and primary results of the SURPASS-1 through SURPASS-4 clinical trials are published (<xref rid="B5" ref-type="bibr">5</xref>–<xref rid="B8" ref-type="bibr">8</xref>). Data from the SURPASS-5 (A Study of Tirzepatide [LY3298176] Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin) study were excluded given the confounder of background of basal insulin use on all its participants (<xref rid="B9" ref-type="bibr">9</xref>). Briefly, the SURPASS clinical trials were randomized controlled clinical studies designed to evaluate the safety and efficacy of tirzepatide (5 mg, 10 mg, or 15 mg) in 5,788 adults with T2D (mean baseline HbA<sub>1c</sub> ranging from 7.94 to 8.52% and BMI ranging from 31.9 to 34.2 kg/m<sup>2</sup>). The primary efficacy measure of HbA<sub>1c</sub> reduction from baseline was superiority of tirzepatide compared with placebo or noninferiority of tirzepatide compared with active comparators (semaglutide 1 mg, insulin degludec, or insulin glargine) at the primary end points of 40 or 52 weeks. Specific BW reduction recommendations regarding diet and exercise beyond the usual practice of each study center were not included in the SURPASS clinical trials. Concomitant therapy that promoted BW reduction was not allowed.</p>
                <p>The SURPASS clinical trials assessed in this analysis were conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. All participants provided signed informed consent, and protocols were approved by local ethical review boards.</p>
              </sec>
              <sec id="s9">
                <title>Baseline Clinical Assessments</title>
                <p>Participant demographics, including age, sex, race, ethnicity, and duration of diabetes, and clinical characteristics, including BW, BMI, waist circumference, previous oral antihyperglycemia medication (OAM) use, tobacco use, and vitals (pulse rate and blood pressure) were obtained at baseline.</p>
              </sec>
              <sec id="s10">
                <title>Laboratory Parameters</title>
                <p>Changes from baseline in cardiometabolic risk factors were evaluated at week 40/42, including HbA<sub>1c</sub>, fasting serum glucose, estimated glomerular filtration rate, lipid profile, and hepatic enzymes. The proportion of patients reaching HbA<sub>1c</sub> targets of &lt;7.0%, ≤6.5%, and &lt;5.7% was also assessed.</p>
              </sec>
              <sec id="s11">
                <title>Statistical Analyses</title>
                <p>Participants from SURPASS-1 through SURPASS-4 adherent to treatment (≥75% doses received and on treatment at week 40/42) and treated with tirzepatide (5 mg, 10 mg, or 15 mg), without rescue glycemic medication and inadvertent enrollment, were included in the analyses. To identify predictors of achieving a BW reduction of ≥15% with tirzepatide, univariate analysis was performed on all demographic and baseline clinical characteristics collected for the assessments of outcomes using logistic regression with tirzepatide dose group as a covariate. Variables associated with achieving a BW reduction of ≥15% with a <italic toggle="yes">P</italic> value &lt;0.2 from univariate analysis were further selected into a multivariate model using stepwise regression with Akaike information criterion. Total cholesterol, LDL cholesterol, and non-HDL cholesterol were closely correlated (Pearson correlation &gt;0.8) with each other, and only non-HDL cholesterol was evaluated with stepwise regression to prevent collinearity in models based on their clinical relevance and role in risk stratification of coronary artery disease (<xref rid="B10" ref-type="bibr">10</xref>). The same rules were applied for choosing triglyceride over VLDL cholesterol and BW over BMI for multivariate modeling. The multivariate model adjusted for tirzepatide dose, metformin use, sex, race, age, baseline HbA<sub>1c</sub>, and baseline BW regardless of their <italic toggle="yes">P</italic> values (base model). To identify clinical characteristics of participants achieving different categorical measures of BW reduction, baseline characteristics and change from baseline to week 40/42 for several efficacy parameters were analyzed. Baseline OAM was classified as “metformin” versus “no metformin.” Other classifications, such as use of sulfonylurea, use of sodium–glucose cotransporter 2 inhibitor, and use of any antihyperglycemia medication were also explored.</p>
              </sec>
              <sec id="s12">
                <title>Data Resource and Availability</title>
                <p>Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the U.S. and European Union and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at <ext-link xlink:href="http://www.vivli.org" ext-link-type="uri">www.vivli.org</ext-link>.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s13">
              <title>Results</title>
              <p>The analyses included 3,188 (83% of all randomized to tirzepatide) participants with T2D from the SURPASS-1 through SURPASS-4 clinical trials who were adherent to tirzepatide treatment (tirzepatide 5 mg, <italic toggle="yes">n</italic> = 1,094; tirzepatide 10 mg, <italic toggle="yes">n</italic> = 1,054; tirzepatide 15 mg, <italic toggle="yes">n</italic> = 1,040). The baseline demographics and clinical characteristics within each trial were similar across treatment arms (<xref rid="B5" ref-type="bibr">5</xref>–<xref rid="B8" ref-type="bibr">8</xref>). Of the 3,188 participants, 756 participants (24%) achieved &lt;5% BW reduction, 878 participants (28%) achieved ≥5 to &lt;10% BW reduction, 762 participants (24%) achieved ≥10 to &lt;15% BW reduction, and 792 participants (25%) achieved ≥15% BW reduction (<xref rid="T1" ref-type="table">Table 1</xref>).</p>
              <table-wrap position="float" id="T1">
                <label>Table 1</label>
                <caption>
                  <p>Baseline demographics and clinical characteristics by BW reduction categories</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th rowspan="1" colspan="1"/>
                      <th align="center" colspan="4" rowspan="1">BW reduction % (week 40/42)</th>
                    </tr>
                    <tr>
                      <th rowspan="1" colspan="1"/>
                      <th align="center" rowspan="1" colspan="1">&lt;5% (<italic toggle="yes">n</italic> = 756)</th>
                      <th align="center" rowspan="1" colspan="1">≥5 to &lt;10% (<italic toggle="yes">n</italic> = 878)</th>
                      <th align="center" rowspan="1" colspan="1">≥10 to &lt;15% (<italic toggle="yes">n</italic> = 762)</th>
                      <th align="center" rowspan="1" colspan="1">≥15% (<italic toggle="yes">n</italic> = 792)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td rowspan="1" colspan="1">Baseline characteristics</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Age, years</td>
                      <td align="center" rowspan="1" colspan="1">56.9 ± 10.2</td>
                      <td align="center" rowspan="1" colspan="1">58.1 ± 10.4</td>
                      <td align="center" rowspan="1" colspan="1">59.2 ± 10.2</td>
                      <td align="center" rowspan="1" colspan="1">57.3 ± 10.4</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Sex</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">  Male</td>
                      <td align="center" rowspan="1" colspan="1">477 (63.1)</td>
                      <td align="center" rowspan="1" colspan="1">514 (58.5)</td>
                      <td align="center" rowspan="1" colspan="1">411 (53.9)</td>
                      <td align="center" rowspan="1" colspan="1">297 (37.5)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">  Female</td>
                      <td align="center" rowspan="1" colspan="1">279 (36.9)</td>
                      <td align="center" rowspan="1" colspan="1">364 (41.5)</td>
                      <td align="center" rowspan="1" colspan="1">351 (46.1)</td>
                      <td align="center" rowspan="1" colspan="1">495 (62.5)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Diabetes duration, years</td>
                      <td align="center" rowspan="1" colspan="1">8.9 ± 6.7</td>
                      <td align="center" rowspan="1" colspan="1">8.9 ± 6.5</td>
                      <td align="center" rowspan="1" colspan="1">9.6 ± 7.2</td>
                      <td align="center" rowspan="1" colspan="1">8.6 ± 7.3</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Current smoker</td>
                      <td align="center" rowspan="1" colspan="1">107 (14.2)</td>
                      <td align="center" rowspan="1" colspan="1">139 (15.8)</td>
                      <td align="center" rowspan="1" colspan="1">121 (15.9)</td>
                      <td align="center" rowspan="1" colspan="1">126 (15.9)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Race</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">  American Indian or Alaska Native</td>
                      <td align="center" rowspan="1" colspan="1">86 (11.4)</td>
                      <td align="center" rowspan="1" colspan="1">105 (12.0)</td>
                      <td align="center" rowspan="1" colspan="1">72 (9.4)</td>
                      <td align="center" rowspan="1" colspan="1">58 (7.3)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">  Asian</td>
                      <td align="center" rowspan="1" colspan="1">49 (6.5)</td>
                      <td align="center" rowspan="1" colspan="1">53 (6.0)</td>
                      <td align="center" rowspan="1" colspan="1">52 (6.8)</td>
                      <td align="center" rowspan="1" colspan="1">49 (6.2)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">  Black or African American</td>
                      <td align="center" rowspan="1" colspan="1">37 (4.9)</td>
                      <td align="center" rowspan="1" colspan="1">33 (3.8)</td>
                      <td align="center" rowspan="1" colspan="1">31 (4.1)</td>
                      <td align="center" rowspan="1" colspan="1">18 (2.3)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">  Other or missing</td>
                      <td align="center" rowspan="1" colspan="1">7 (0.9)</td>
                      <td align="center" rowspan="1" colspan="1">9 (1.0)</td>
                      <td align="center" rowspan="1" colspan="1">7 (0.9)</td>
                      <td align="center" rowspan="1" colspan="1">8 (1.0)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> White</td>
                      <td align="center" rowspan="1" colspan="1">577 (76.3)</td>
                      <td align="center" rowspan="1" colspan="1">678 (77.2)</td>
                      <td align="center" rowspan="1" colspan="1">600 (78.7)</td>
                      <td align="center" rowspan="1" colspan="1">659 (83.2)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Ethnicity</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">  Hispanic or Latino</td>
                      <td align="center" rowspan="1" colspan="1">386 (51.1)</td>
                      <td align="center" rowspan="1" colspan="1">459 (52.3)</td>
                      <td align="center" rowspan="1" colspan="1">403 (52.9)</td>
                      <td align="center" rowspan="1" colspan="1">389 (49.1)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">  Not Hispanic or Latino</td>
                      <td align="center" rowspan="1" colspan="1">345 (45.6)</td>
                      <td align="center" rowspan="1" colspan="1">398 (45.3)</td>
                      <td align="center" rowspan="1" colspan="1">345 (45.3)</td>
                      <td align="center" rowspan="1" colspan="1">392 (49.5)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">  Not reported</td>
                      <td align="center" rowspan="1" colspan="1">25 (3.3)</td>
                      <td align="center" rowspan="1" colspan="1">21 (2.4)</td>
                      <td align="center" rowspan="1" colspan="1">14 (1.8)</td>
                      <td align="center" rowspan="1" colspan="1">11 (1.4)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Baseline antihyperglycemia therapy</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Metformin only</td>
                      <td align="center" rowspan="1" colspan="1">443 (58.6)</td>
                      <td align="center" rowspan="1" colspan="1">533 (60.7)</td>
                      <td align="center" rowspan="1" colspan="1">503 (66.0)</td>
                      <td align="center" rowspan="1" colspan="1">528 (66.7)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> None</td>
                      <td align="center" rowspan="1" colspan="1">86 (11.4)</td>
                      <td align="center" rowspan="1" colspan="1">106 (12.1)</td>
                      <td align="center" rowspan="1" colspan="1">55 (7.2)</td>
                      <td align="center" rowspan="1" colspan="1">57 (7.2)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> SGLT2i ± metformin</td>
                      <td align="center" rowspan="1" colspan="1">95 (12.6)</td>
                      <td align="center" rowspan="1" colspan="1">109 (12.4)</td>
                      <td align="center" rowspan="1" colspan="1">88 (11.5)</td>
                      <td align="center" rowspan="1" colspan="1">111 (14.0)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Sulfonylurea (any)<sup><xref rid="tblfn2" ref-type="table-fn">a</xref></sup></td>
                      <td align="center" rowspan="1" colspan="1">132 (17.5)</td>
                      <td align="center" rowspan="1" colspan="1">130 (14.8)</td>
                      <td align="center" rowspan="1" colspan="1">116 (15.2)</td>
                      <td align="center" rowspan="1" colspan="1">96 (12.1)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Clinical baseline characteristics</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> HbA<sub>1c</sub>, %</td>
                      <td align="center" rowspan="1" colspan="1">8.5 ± 1.0</td>
                      <td align="center" rowspan="1" colspan="1">8.4 ± 1.0</td>
                      <td align="center" rowspan="1" colspan="1">8.3 ± 1.0</td>
                      <td align="center" rowspan="1" colspan="1">8.1 ± 0.9</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Fasting serum glucose, mg/dL</td>
                      <td align="center" rowspan="1" colspan="1">177.3 ± 52.1</td>
                      <td align="center" rowspan="1" colspan="1">173.1 ± 50.4</td>
                      <td align="center" rowspan="1" colspan="1">173.5 ± 50.7</td>
                      <td align="center" rowspan="1" colspan="1">163.9 ± 45.9</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Weight, kg</td>
                      <td align="center" rowspan="1" colspan="1">95.6 ± 21.8</td>
                      <td align="center" rowspan="1" colspan="1">93.4 ± 20.0</td>
                      <td align="center" rowspan="1" colspan="1">91.6 ± 18.7</td>
                      <td align="center" rowspan="1" colspan="1">91.6 ± 20.8</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> BMI, kg/m<sup>2</sup></td>
                      <td align="center" rowspan="1" colspan="1">33.9 ± 6.4</td>
                      <td align="center" rowspan="1" colspan="1">33.5 ± 6.6</td>
                      <td align="center" rowspan="1" colspan="1">33.2 ± 5.7</td>
                      <td align="center" rowspan="1" colspan="1">34.0 ± 6.7</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Waist circumference, cm</td>
                      <td align="center" rowspan="1" colspan="1">110.5 ± 15.1</td>
                      <td align="center" rowspan="1" colspan="1">109.2 ± 14.4</td>
                      <td align="center" rowspan="1" colspan="1">108.5 ± 14.1</td>
                      <td align="center" rowspan="1" colspan="1">109.2 ± 15.1</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Systolic blood pressure, mmHg</td>
                      <td align="center" rowspan="1" colspan="1">132.0 ± 13.7</td>
                      <td align="center" rowspan="1" colspan="1">131.2 ± 13.4</td>
                      <td align="center" rowspan="1" colspan="1">131.7 ± 14.4</td>
                      <td align="center" rowspan="1" colspan="1">130.8 ± 14.9</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Diastolic blood pressure, mmHg</td>
                      <td align="center" rowspan="1" colspan="1">79.7 ± 8.9</td>
                      <td align="center" rowspan="1" colspan="1">79.1 ± 8.7</td>
                      <td align="center" rowspan="1" colspan="1">78.4 ± 8.9</td>
                      <td align="center" rowspan="1" colspan="1">79.2 ± 9.3</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> eGFR, mL/min/1.73 m<sup>2</sup></td>
                      <td align="center" rowspan="1" colspan="1">95.1 ± 19.1</td>
                      <td align="center" rowspan="1" colspan="1">91.9 ± 19.2</td>
                      <td align="center" rowspan="1" colspan="1">89.9 ± 19.6</td>
                      <td align="center" rowspan="1" colspan="1">91.9 ± 19.1</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Total cholesterol, mg/dL</td>
                      <td align="center" rowspan="1" colspan="1">173.2 ± 41.2</td>
                      <td align="center" rowspan="1" colspan="1">175.4 ± 43.6</td>
                      <td align="center" rowspan="1" colspan="1">169.9 ± 42.6</td>
                      <td align="center" rowspan="1" colspan="1">168.5 ± 40.6</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Non-HDL cholesterol, mg/dL</td>
                      <td align="center" rowspan="1" colspan="1">130.2 ± 39.3</td>
                      <td align="center" rowspan="1" colspan="1">132.1 ± 42.7</td>
                      <td align="center" rowspan="1" colspan="1">126.6 ± 40.8</td>
                      <td align="center" rowspan="1" colspan="1">124.1 ± 38.5</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> HDL cholesterol, mg/dL</td>
                      <td align="center" rowspan="1" colspan="1">43.1 ± 11.3</td>
                      <td align="center" rowspan="1" colspan="1">43.3 ± 10.6</td>
                      <td align="center" rowspan="1" colspan="1">43.3 ± 10.9</td>
                      <td align="center" rowspan="1" colspan="1">44.1 ± 11.9</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> LDL cholesterol, mg/dL</td>
                      <td align="center" rowspan="1" colspan="1">94.2 ± 35.1</td>
                      <td align="center" rowspan="1" colspan="1">93.9 ± 35.2</td>
                      <td align="center" rowspan="1" colspan="1">91.0 ± 36.0</td>
                      <td align="center" rowspan="1" colspan="1">90.1 ± 33.6</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Triglycerides, mg/dL</td>
                      <td align="center" rowspan="1" colspan="1">189.6 ± 118.4</td>
                      <td align="center" rowspan="1" colspan="1">202.2 ± 160.9</td>
                      <td align="center" rowspan="1" colspan="1">184.6 ± 104.0</td>
                      <td align="center" rowspan="1" colspan="1">178.5 ± 123.0</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> ALT, IU/L</td>
                      <td align="center" rowspan="1" colspan="1">30.1 ± 17.8</td>
                      <td align="center" rowspan="1" colspan="1">28.6 ± 19.3</td>
                      <td align="center" rowspan="1" colspan="1">28.5 ± 17.1</td>
                      <td align="center" rowspan="1" colspan="1">27.9 ± 16.4</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> AST, IU/L</td>
                      <td align="center" rowspan="1" colspan="1">23.5 ± 13.2</td>
                      <td align="center" rowspan="1" colspan="1">22.7 ± 13.0</td>
                      <td align="center" rowspan="1" colspan="1">22.3 ± 12.2</td>
                      <td align="center" rowspan="1" colspan="1">22.4 ± 11.9</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="tblfn1">
                    <p>Descriptive statistics are presented as mean ± SD for continuous variables and <italic toggle="yes">n</italic> (%) for categorical variables and were calculated for baseline values. Note: The race categories of “Multiple,” “Native Hawaiian or Other Pacific Islander,” and “Missing” were merged in the “Other or missing” category for analysis. eGFR, estimated glomerular filtration rate; SGLT2i, sodium–glucose cotransporter 2 inhibitor.</p>
                  </fn>
                  <fn id="tblfn2">
                    <label>a</label>
                    <p>The term “any” refers sulfonylurea only, ± SGLT2i use, and ± metformin use.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="s14">
                <title>Potential Predictors of Achieving a BW Reduction of ≥15% With Tirzepatide</title>
                <p>Univariate analyses found the following baseline factors were independently associated (<italic toggle="yes">P</italic> &lt; 0.2) with higher odds of achieving a BW reduction of ≥15% after adjusting for tirzepatide doses: female sex, White or Asian race, non-Hispanic ethnicity, antihyperglycemia medications, being treated with metformin, not being treated with sulfonylurea, age, T2D duration, baseline HDL cholesterol, ALT, HbA<sub>1c</sub>, BW, systolic blood pressure, fasting serum glucose, fasting serum triglycerides, and non-HDL cholesterol. A stepwise regression with base model covariates was then performed on those associated variables from the univariate regression to build a multivariate model. The final multivariate model included fasting serum glucose and non-HDL cholesterol as predictors in addition to the base model covariates, which included age, sex, race, BW, HbA<sub>1c</sub>, tirzepatide dose, and baseline metformin use (<xref rid="F1" ref-type="fig">Fig. 1</xref>). The multivariate analysis of these covariates showed that higher tirzepatide dose, female sex, White or Asian race, younger age, receiving metformin, lower HbA<sub>1c</sub>, fasting serum glucose, non-HDL cholesterol at baseline were significantly associated with higher odds of achieving a ≥15% BW reduction with tirzepatide treatment.</p>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>Multivariate analysis of demographic variables, baseline OAM, and laboratory parameters. Note: The odds ratios (ORs) for base model parameters were calculated from a logistic regression model with tirzepatide dose, baseline OAM, sex, race, age, baseline HbA<sub>1c</sub>, and baseline weight. The odds ratios for additional laboratory parameters were calculated from the logistic regression with each baseline laboratory parameter added to the base model parameters, respectively.</p>
                  </caption>
                  <graphic xlink:href="dc231135f1" position="float"/>
                </fig>
              </sec>
              <sec id="s15">
                <title>Characterization of Achieving Different Categorical Measures of BW Reduction With Tirzepatide</title>
                <p>Participants achieving higher categorical BW reduction categories were more likely to be women, White race (compared with American Indian or Alaska Native, Asian, Black or African American, or other), and on metformin at baseline (<xref rid="T1" ref-type="table">Table 1</xref>). There were no apparent differences across the groups in mean age, T2D duration, or current smoker status. Higher BW reduction categories were associated with greater reductions in HbA<sub>1c</sub>, fasting serum glucose, waist circumference, blood pressure, serum triglycerides, and serum ALT.</p>
              </sec>
              <sec id="s16">
                <title>Changes in Cardiometabolic Parameters With Differing Categorical BW Reduction</title>
                <p>Higher BW reduction was associated with greater chance of achieving HbA<sub>1c</sub> &lt;5.7% (<xref rid="T2" ref-type="table">Table 2</xref>). Clinical characteristics by BW reduction subgroups over time are presented in <xref rid="F2" ref-type="fig">Fig. 2</xref>. Overall, improvements in cardiometabolic parameters were categorically associated with weight reduction. Mean BW reductions reached −18.5 kg (−20.1%) at week 40/42. Participants who achieved a BW reduction of ≥15% reached a mean BW of 73 kg, with a mean waist circumference of 94 cm at week 40/42 (<xref rid="F2" ref-type="fig">Figs. 2<italic toggle="yes">A</italic> and <italic toggle="yes">B</italic></xref>). Participants who achieved a BW reduction of ≥15% experienced a mean reduction in HbA<sub>1c</sub> from 8.1% at baseline to 5.5% at week 40/42 (<xref rid="F2" ref-type="fig">Fig. 2<italic toggle="yes">C</italic></xref>). Furthermore, mean systolic blood pressure decreased from 131 mmHg at baseline to 120 mmHg (<xref rid="F2" ref-type="fig">Fig. 2<italic toggle="yes">D</italic></xref>), with mean decreases in triglycerides from 179 mg/dL to 121 mg/dL (<xref rid="F2" ref-type="fig">Fig. 2<italic toggle="yes">E</italic></xref>) and in ALT from 28 IU/L to 18 IU/L (<xref rid="F2" ref-type="fig">Fig. 2<italic toggle="yes">F</italic></xref>).</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Assessment of efficacy parameters and safety profile by BW reduction categories</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" colspan="4" rowspan="1">BW reduction % (week 40/42)</th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">&lt;5% (n = 756)</th>
                        <th align="center" rowspan="1" colspan="1">≥5 to &lt;10% (<italic toggle="yes">n</italic> = 878)</th>
                        <th align="center" rowspan="1" colspan="1">≥10 to &lt;15% (<italic toggle="yes">n</italic> = 762)</th>
                        <th align="center" rowspan="1" colspan="1">≥15% (<italic toggle="yes">n</italic> = 792)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">HbA<sub>1c</sub>, %</td>
                        <td align="center" rowspan="1" colspan="1">−1.9 ± 1.2</td>
                        <td align="center" rowspan="1" colspan="1">−2.3 ± 1.1</td>
                        <td align="center" rowspan="1" colspan="1">−2.5 ± 1.0</td>
                        <td align="center" rowspan="1" colspan="1">−2.6 ± 0.9</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Participants reaching HbA<sub>1c</sub></td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &lt;7%</td>
                        <td align="center" rowspan="1" colspan="1">548 (72.9)</td>
                        <td align="center" rowspan="1" colspan="1">788 (89.9)</td>
                        <td align="center" rowspan="1" colspan="1">724 (95.3)</td>
                        <td align="center" rowspan="1" colspan="1">778 (98.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≤6.5%</td>
                        <td align="center" rowspan="1" colspan="1">415 (55.2)</td>
                        <td align="center" rowspan="1" colspan="1">705 (80.4)</td>
                        <td align="center" rowspan="1" colspan="1">698 (91.8)</td>
                        <td align="center" rowspan="1" colspan="1">761 (96.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &lt;5.7%</td>
                        <td align="center" rowspan="1" colspan="1">93 (12.4)</td>
                        <td align="center" rowspan="1" colspan="1">243 (27.7)</td>
                        <td align="center" rowspan="1" colspan="1">347 (45.7)</td>
                        <td align="center" rowspan="1" colspan="1">510 (64.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Fasting serum glucose, mg/dL</td>
                        <td align="center" rowspan="1" colspan="1">−46.0 ± 55.4</td>
                        <td align="center" rowspan="1" colspan="1">−58.1 ± 49.4</td>
                        <td align="center" rowspan="1" colspan="1">−65.7 ± 49.7</td>
                        <td align="center" rowspan="1" colspan="1">−66.6 ± 45.3</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Weight, kg (%)</td>
                        <td align="center" rowspan="1" colspan="1">−1.7 ± 2.6 (−2)</td>
                        <td align="center" rowspan="1" colspan="1">−7.1 ± 2.1 (−8)</td>
                        <td align="center" rowspan="1" colspan="1">−11.3 ± 2.6 (−12)</td>
                        <td align="center" rowspan="1" colspan="1">−18.5 ± 6.0 (−20)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td>
                        <td align="center" rowspan="1" colspan="1">−0.6 ± 0.9</td>
                        <td align="center" rowspan="1" colspan="1">−2.5 ± 0.7</td>
                        <td align="center" rowspan="1" colspan="1">−4.1 ± 0.9</td>
                        <td align="center" rowspan="1" colspan="1">−6.9 ± 2.1</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Waist circumference, cm</td>
                        <td align="center" rowspan="1" colspan="1">−2.4 ± 7.3</td>
                        <td align="center" rowspan="1" colspan="1">−6.4 ± 6.8</td>
                        <td align="center" rowspan="1" colspan="1">−9.5 ± 7.5</td>
                        <td align="center" rowspan="1" colspan="1">−15.1 ± 9.0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Systolic blood pressure, mmHg</td>
                        <td align="center" rowspan="1" colspan="1">−2.4 ± 13.0</td>
                        <td align="center" rowspan="1" colspan="1">−4.6 ± 14.1</td>
                        <td align="center" rowspan="1" colspan="1">−6.8 ± 14.4</td>
                        <td align="center" rowspan="1" colspan="1">−10.3 ± 15.8</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Diastolic blood pressure, mmHg</td>
                        <td align="center" rowspan="1" colspan="1">−0.8 ± 8.4</td>
                        <td align="center" rowspan="1" colspan="1">−1.7 ± 8.8</td>
                        <td align="center" rowspan="1" colspan="1">−2.7 ± 9.1</td>
                        <td align="center" rowspan="1" colspan="1">−4.3 ± 9.9</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">eGFR, mL/min/1.73 m<sup>2</sup></td>
                        <td align="center" rowspan="1" colspan="1">−4.7 ± 10.0</td>
                        <td align="center" rowspan="1" colspan="1">−3.8 ± 9.9</td>
                        <td align="center" rowspan="1" colspan="1">−3.2 ± 11.0</td>
                        <td align="center" rowspan="1" colspan="1">−3.2 ± 12.2</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Total cholesterol, %</td>
                        <td align="center" rowspan="1" colspan="1">−0.1 ± 21.0</td>
                        <td align="center" rowspan="1" colspan="1">−5.1 ± 21.1</td>
                        <td align="center" rowspan="1" colspan="1">−4.6 ± 21.2</td>
                        <td align="center" rowspan="1" colspan="1">−6.8 ± 20.2</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Non-HDL cholesterol, %</td>
                        <td align="center" rowspan="1" colspan="1">−0.7 ± 28.7</td>
                        <td align="center" rowspan="1" colspan="1">−8.1 ± 28.0</td>
                        <td align="center" rowspan="1" colspan="1">−8.4 ± 29.0</td>
                        <td align="center" rowspan="1" colspan="1">−12.2 ± 27.2</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HDL cholesterol, %</td>
                        <td align="center" rowspan="1" colspan="1">4.7 ± 20.0</td>
                        <td align="center" rowspan="1" colspan="1">7.2 ± 18.1</td>
                        <td align="center" rowspan="1" colspan="1">9.5 ± 18.7</td>
                        <td align="center" rowspan="1" colspan="1">11.5 ± 19.3</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">LDL cholesterol, %</td>
                        <td align="center" rowspan="1" colspan="1">1.8 ± 39.2</td>
                        <td align="center" rowspan="1" colspan="1">−1.9 ± 46.8</td>
                        <td align="center" rowspan="1" colspan="1">−0.3 ± 41.6</td>
                        <td align="center" rowspan="1" colspan="1">−3.6 ± 41.8</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Triglycerides, %</td>
                        <td align="center" rowspan="1" colspan="1">1.9 ± 45.4</td>
                        <td align="center" rowspan="1" colspan="1">−11.7 ± 40.9</td>
                        <td align="center" rowspan="1" colspan="1">−17.9 ± 37.3</td>
                        <td align="center" rowspan="1" colspan="1">−24.2 ± 33.3</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ALT, %</td>
                        <td align="center" rowspan="1" colspan="1">−4.5 ± 43.2</td>
                        <td align="center" rowspan="1" colspan="1">−14.6 ± 41.7</td>
                        <td align="center" rowspan="1" colspan="1">−23.4 ± 38.9</td>
                        <td align="center" rowspan="1" colspan="1">−22.1 ± 70.8</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">AST, %</td>
                        <td align="center" rowspan="1" colspan="1">2.2 ± 37.4</td>
                        <td align="center" rowspan="1" colspan="1">−4.5 ± 34.5</td>
                        <td align="center" rowspan="1" colspan="1">−8.9 ± 33.9</td>
                        <td align="center" rowspan="1" colspan="1">−8.6 ± 53.8</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Participants with ≥1 serious adverse event</td>
                        <td align="center" rowspan="1" colspan="1">32 (4.2)</td>
                        <td align="center" rowspan="1" colspan="1">37 (4.2)</td>
                        <td align="center" rowspan="1" colspan="1">30 (3.9)</td>
                        <td align="center" rowspan="1" colspan="1">31 (3.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Participants with ≥1 TEAE</td>
                        <td align="center" rowspan="1" colspan="1">420 (55.6)</td>
                        <td align="center" rowspan="1" colspan="1">515 (58.7)</td>
                        <td align="center" rowspan="1" colspan="1">470 (61.7)</td>
                        <td align="center" rowspan="1" colspan="1">540 (68.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">TEAEs occurring in ≥5% of participants in any BW reduction category by preferred term</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nausea</td>
                        <td align="center" rowspan="1" colspan="1">77 (10.2)</td>
                        <td align="center" rowspan="1" colspan="1">128 (14.6)</td>
                        <td align="center" rowspan="1" colspan="1">123 (16.1)</td>
                        <td align="center" rowspan="1" colspan="1">183 (23.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Diarrhea</td>
                        <td align="center" rowspan="1" colspan="1">103 (13.6)</td>
                        <td align="center" rowspan="1" colspan="1">112 (12.8)</td>
                        <td align="center" rowspan="1" colspan="1">103 (13.5)</td>
                        <td align="center" rowspan="1" colspan="1">128 (16.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Decreased appetite</td>
                        <td align="center" rowspan="1" colspan="1">27 (3.6)</td>
                        <td align="center" rowspan="1" colspan="1">60 (6.8)</td>
                        <td align="center" rowspan="1" colspan="1">65 (8.5)</td>
                        <td align="center" rowspan="1" colspan="1">85 (10.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Dyspepsia</td>
                        <td align="center" rowspan="1" colspan="1">47 (6.2)</td>
                        <td align="center" rowspan="1" colspan="1">49 (5.6)</td>
                        <td align="center" rowspan="1" colspan="1">58 (7.6)</td>
                        <td align="center" rowspan="1" colspan="1">55 (6.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Vomiting</td>
                        <td align="center" rowspan="1" colspan="1">30 (4.0)</td>
                        <td align="center" rowspan="1" colspan="1">37 (4.2)</td>
                        <td align="center" rowspan="1" colspan="1">44 (5.8)</td>
                        <td align="center" rowspan="1" colspan="1">65 (8.2)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn3">
                      <p>Data are mean ± SD change, <italic toggle="yes">n</italic> (%), or percentage change from baseline at week 40/42, unless otherwise noted, with <italic toggle="yes">n</italic> indicating pooled number of participants across SURPASS-1 through SURPASS-4 tirzepatide doses Percentage change in BW is presented in parenthesis. Lipid data are percentage change from baseline. Note: Waist circumference data for SURPASS-4 were not available at weeks 40/42 so week 36 measures were used.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" id="F2">
                  <label>Figure 2</label>
                  <caption>
                    <p>Clinical characteristics over time by BW reduction categories. BW (<italic toggle="yes">A</italic>), waist circumference (<italic toggle="yes">B</italic>), HbA<sub>1c</sub> (<italic toggle="yes">C</italic>), systolic blood pressure (<italic toggle="yes">D</italic>), triglycerides (<italic toggle="yes">E</italic>), and ALT (<italic toggle="yes">F</italic>). Data are least squares mean (SE) actual values over time from baseline to week 40. Least squares mean values were calculated from mixed-model repeated-measures model: value = treatment + time + treatment ∗ time.</p>
                  </caption>
                  <graphic xlink:href="dc231135f2" position="float"/>
                </fig>
              </sec>
              <sec id="s17">
                <title>Safety</title>
                <p>Across the population analyzed, at least one treatment-emergent adverse event (TEAE) was reported by 56%, 59%, 62%, and 68% of participants who achieved a BW reduction of &lt;5%, ≥5 to &lt;10%, ≥10 to &lt;15%, and ≥15%, respectively (<xref rid="T2" ref-type="table">Table 2</xref>). The most common TEAEs were gastrointestinal-related (32% vs. 36% vs. 39% vs. 46%, respectively). A similar number of participants experienced serious adverse events across groups (4.2% vs. 4.2% vs. 3.9% vs 3.9%, respectively) (<xref rid="T2" ref-type="table">Table 2</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="s18">
              <title>Conclusions</title>
              <p>Achieving a substantial and sustainable BW reduction (i.e., 10–15%) in individuals living with T2D and obesity is an important clinical goal supported by guidelines as it may prevent or delay many chronic diabetes-related complications (<xref rid="B11" ref-type="bibr">11</xref>–<xref rid="B14" ref-type="bibr">14</xref>). In some cases, higher BW reduction may lead to sustained glycemic control and diabetes remission (<xref rid="B15" ref-type="bibr">15</xref>). In the SURPASS 1–4 studies, most participants with T2D treated with tirzepatide achieved clinically meaningful weight reduction of varying magnitudes, particularly at higher doses. In these analyses, approximately one in four participants achieved a ≥15% BW reduction after 40 weeks of treatment with tirzepatide. The substantial weight reduction observed with tirzepatide is considered to be the result of glucose-dependent insulinotropic polypeptide receptor activation acting synergistically with GLP-1 receptor activation (<xref rid="B4" ref-type="bibr">4</xref>–<xref rid="B8" ref-type="bibr">8</xref>).</p>
              <p>Factors associated with greater odds of achieving a ≥15% BW reduction were higher doses of tirzepatide, concurrent use of metformin, female sex, White or Asian race, younger age, and lower HbA<sub>1c</sub>, fasting serum glucose, and non-HDL cholesterol at baseline. The observation that treatment with higher tirzepatide doses was more likely to lead to a ≥15% BW reduction is consistent with dose-dependent BW reduction seen across the SURPASS program (<xref rid="B5" ref-type="bibr">5</xref>–<xref rid="B9" ref-type="bibr">9</xref>). Additionally, concurrent use of metformin was associated with achieving a ≥15% BW reduction. This finding aligns with the known modest weight-lowering effect of metformin in adults with T2D likely related to its appetite-reducing effect (<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>). Accordingly, the weight-lowering effect of tirzepatide appears greater when used in combination with metformin versus as monotherapy, although these trials were not designed for direct comparisons (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). We also observed that better glycemic control at baseline was associated with greater BW reduction, similar to what has been observed in bariatric surgery as a predictor of the weight reduction response (<xref rid="B18" ref-type="bibr">18</xref>). In addition, individual predisposition may also play a role in the weight and glycemic responses to tirzepatide, and further research should provide more information on this topic.</p>
              <p>The observation that women are more likely than men to achieve a ≥15% BW reduction with tirzepatide treatment has also been made in other pharmacotherapy or bariatric surgery studies (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>). The underlying mechanism is unknown for why women tend to lose more weight compared with men in various BW reduction intervention studies, but there are potential physiological factors, such as differential body fat distributions by sex and proportionally greater fat mass in women, influencing the variability of responses to BW reduction interventions depending on sex (<xref rid="B20" ref-type="bibr">20</xref>).</p>
              <p>This study showed that African American and American Indian/Alaska Native individuals had lower odds of achieving a ≥15% BW reduction compared with White individuals. Previous analyses of the selective GLP-1 receptor agonist semaglutide did not show similar findings, but the data were limited in the number achieving a ≥15% BW reduction (<xref rid="B21" ref-type="bibr">21</xref>). On the other hand, similar observations were made in bariatric surgery literature with a decreased BW reduction response in African American compared with White individuals (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Given the limited sample size of African American and American Indian/Alaska Native individuals in this analysis and the lack of socioeconomic data needed to fully understand the context, results regarding race as predictor of weight reduction with tirzepatide treatment should be interpreted with caution. Further research is needed to understand the impact of race on BW reduction.</p>
              <p>Also, younger age was associated with higher odds of achieving a ≥15% BW reduction. This observation adds to the mixed results in the literature, including higher BW reduction in younger adults after bariatric surgery, but higher odds of BW reduction in older adults with behavioral or lifestyle interventions (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B24" ref-type="bibr">24</xref>–<xref rid="B26" ref-type="bibr">26</xref>). Notably, baseline BW was not predictive of achieving a ≥15% BW reduction with tirzepatide treatment. In other words, most of the individuals with T2D receiving tirzepatide achieved a clinically meaningful BW reduction regardless of their baseline BW.</p>
              <p>With higher weight reduction, participants achieved greater improvements in HbA<sub>1c</sub> and other cardiometabolic parameters, including waist circumference, blood pressure, lipids, and liver enzymes, in particular serum ALT, which has been associated with liver fat in people with T2D (<xref rid="B27" ref-type="bibr">27</xref>). Specifically, among those achieving a ≥15% BW reduction, there was a mean decrease in systolic blood pressure by up to 10 mmHg, in triglycerides by &gt;20 mg/dL, and in ALT by &gt;20%. Additionally, we observed that the number of participants who achieved normoglycemia (HbA<sub>1c</sub> &lt;5.7%) with tirzepatide treatment increased with higher weight reduction categories, such that &gt;60% of those achieving a ≥15% BW reduction also achieved normoglycemia. Combined, these observations demonstrate that the cardiometabolic benefits are likely greater with a higher BW reduction with tirzepatide treatment. A dedicated study, SURPASS-CVOT (A Study of Tirzepatide [LY3298176] Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes, NCT04255433]), is ongoing to assess whether such risk factor changes will contribute to meaningful cardioprotective benefits of higher-dose tirzepatide in patients with T2D relative to dulaglutide, which leads to far less weight loss.</p>
              <p>Regarding the safety data associated with greater BW reduction, we observed similarly low rates of adverse events across the different weight loss groups, with numerically higher rates of gastrointestinal adverse events seen with greater weight loss. This observation is likely due to the greater proportion of participants treated with tirzepatide 15 mg in these subgroups and not a direct result of gastrointestinal adverse events influencing BW reduction. In the SURPASS program, a slightly higher rate of gastrointestinal adverse events was observed in participants treated with tirzepatide 15 mg; however, post hoc analyses suggest that gastrointestinal adverse events have little to no impact on tirzepatide-induced BW reduction (<xref rid="B28" ref-type="bibr">28</xref>).</p>
              <p>The strengths of this analysis include a large number of well-characterized participants across the disease continuum in a large phase 3 clinical trial program and a well-balanced number of participants who have achieved various categorical weight loss evaluated in this study, including ≥15% BW. Limitations include the post hoc analysis design focused on those adherent to treatment and the limited follow-up period that may not be adequate for some to reach the BW plateau with tirzepatide treatment. This work focused on baseline factors as potential predictors of weight reduction. In the future, the predictor model may be enhanced by incorporating postbaseline and genetic data. Also, the studies were far too short to see any impacts on long-term cardiovascular outcomes.</p>
              <p>In conclusion, the majority adherent to tirzepatide in SURPASS 1–4 studies achieved a clinically meaningful BW reduction, and one in four (25%, <italic toggle="yes">n</italic> = 792) achieved a ≥15% weight reduction with tirzepatide treatment. Factors associated with a higher likelihood of achieving a ≥15% BW reduction in these studies were higher tirzepatide doses, female sex, White or Asian race, younger age, receiving metformin, better glycemic status, and lower non-HDL cholesterol at baseline. With greater BW reduction, participants achieved larger improvements in glycemia and cardiometabolic parameters, including waist circumference, blood pressure, lipids, and liver enzymes. These findings may provide valuable information to clinicians and people with T2D regarding the likelihood of achieving substantial BW reduction with tirzepatide. They also help to signal likely improvements to be seen in a range of cardiometabolic risk parameters with tirzepatide-induced weight loss. Ongoing trials will determine impact of such changes on cardiovascular outcomes.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>Article Information</title>
              <p><bold>Acknowledgments.</bold> The authors thank Chrisanthi A. Karanikas, MS (Eli Lilly and Company) for her writing and editorial assistance.</p>
              <p content-type="COI-statement"><bold>Duality of Interest.</bold> This study was supported by Eli Lilly and Company. M.T.M. has received honoraria from Abbott, Alfa-Sigma, AstraZeneca, Ascentia, Adamed, Bayer, Berlin-Chemie, Boehringer Ingelheim, Dexcom, Eli Lilly and Company, Krka, Medtronic, Merck, Novo Nordisk, Sanofi, Sandoz, and Servier. R.L.B. has participated in speakers bureaus for Novo Nordisk, Eli Lilly and Company, and ViiV Healthcare, reports research grant support from Novo Nordisk and consultancy with Boehringer Ingelheim, Eli Lilly and Company, Gila Therapeutics Inc, GSK, Novo Nordisk, and Pfizer, and became an employee and shareholder of Eli Lilly and Company at the time of this study. N.S. has consulted for Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Hanmi Pharmaceuticals, Novo Nordisk, Novartis, Sanofi, and Pfizer, and received grant support from Boehringer Ingelheim. C.J.L., A.R., B.K.B., G.G., and J.L. are employees and shareholders of Eli Lilly and Company. H.W. is contracted by Eli Lilly and Company. No other potential conflicts of interest relevant to this article were reported.</p>
              <p><bold>Author Contributions.</bold> Á.R., B.K.B., and C.J.L. conducted and provided medical oversight during the trial. H.W. was responsible for the statistical analyses. H.W. and C.J.L. contributed to the post hoc design. All authors participated in interpretation of the data and critical review of the manuscript, had full access to all the data in the study, and approved of this manuscript to be submitted for publication. C.J.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
              <p><bold>Prior Presentation.</bold> Parts of this study were presented in abstract form at the International Diabetes Federation (IDF) World Diabetes Congress, Lisbon, Portugal, 5–8 December 2022.</p>
            </ack>
            <fn-group>
              <fn>
                <p>Clinical trial reg. no. <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03954834" ext-link-type="uri">NCT03954834</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03987919" ext-link-type="uri">NCT03987919</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03882970" ext-link-type="uri">NCT03882970</ext-link>, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03730662" ext-link-type="uri">NCT03730662</ext-link>, <ext-link xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">clinicaltrials.gov</ext-link></p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tobin</surname><given-names>B</given-names></string-name>, <string-name><surname>Miller</surname><given-names>G</given-names></string-name></person-group>. <article-title>Symposium: nutritional and metabolic diversity: understanding the basis of biologic variance in the obesity/diabetes/cardiovascular disease connection. Introduction</article-title>. <source>J Nutr</source><year>2001</year>;<volume>131</volume>:<fpage>333S</fpage>–<lpage>335S</lpage><pub-id pub-id-type="pmid">11160556</pub-id>
</mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lean</surname><given-names>MEJ</given-names></string-name>, <string-name><surname>Leslie</surname><given-names>WS</given-names></string-name>, <string-name><surname>Barnes</surname><given-names>AC</given-names></string-name>, <etal/></person-group>. <article-title>Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial</article-title>. <source>Lancet Diabetes Endocrinol</source><year>2019</year>;<volume>7</volume>:<fpage>344</fpage>–<lpage>355</lpage><pub-id pub-id-type="pmid">30852132</pub-id>
</mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davies</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Aroda</surname><given-names>VR</given-names></string-name>, <string-name><surname>Collins</surname><given-names>BS</given-names></string-name>, <etal/></person-group>. <article-title>Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title>. <source>Diabetes Care</source><year>2022</year>;<volume>45</volume>:<fpage>2753</fpage>–<lpage>2786</lpage><pub-id pub-id-type="pmid">36148880</pub-id>
</mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coskun</surname><given-names>T</given-names></string-name>, <string-name><surname>Sloop</surname><given-names>KW</given-names></string-name>, <string-name><surname>Loghin</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept</article-title>. <source>Mol Metab</source><year>2018</year>;<volume>18</volume>:<fpage>3</fpage>–<lpage>14</lpage><pub-id pub-id-type="pmid">30473097</pub-id>
</mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosenstock</surname><given-names>J</given-names></string-name>, <string-name><surname>Wysham</surname><given-names>C</given-names></string-name>, <string-name><surname>Frías</surname><given-names>JP</given-names></string-name>, <etal/></person-group>. <article-title>Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial</article-title>. <source>Lancet</source><year>2021</year>;<volume>398</volume>:<fpage>143</fpage>–<lpage>155</lpage><pub-id pub-id-type="pmid">34186022</pub-id>
</mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frías</surname><given-names>JP</given-names></string-name>, <string-name><surname>Davies</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Rosenstock</surname><given-names>J</given-names></string-name>, <etal/>.; <collab>SURPASS-2 Investigators</collab></person-group>. <article-title>Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2021</year>;<volume>385</volume>:<fpage>503</fpage>–<lpage>515</lpage><pub-id pub-id-type="pmid">34170647</pub-id>
</mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ludvik</surname><given-names>B</given-names></string-name>, <string-name><surname>Giorgino</surname><given-names>F</given-names></string-name>, <string-name><surname>Jódar</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial</article-title>. <source>Lancet</source><year>2021</year>;<volume>398</volume>:<fpage>583</fpage>–<lpage>598</lpage><pub-id pub-id-type="pmid">34370970</pub-id>
</mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Del Prato</surname><given-names>S</given-names></string-name>, <string-name><surname>Kahn</surname><given-names>SE</given-names></string-name>, <string-name><surname>Pavo</surname><given-names>I</given-names></string-name>, <etal/>.; <collab>SURPASS-4 Investigators</collab></person-group>. <article-title>Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial</article-title>. <source>Lancet</source><year>2021</year>;<volume>398</volume>:<fpage>1811</fpage>–<lpage>1824</lpage><pub-id pub-id-type="pmid">34672967</pub-id>
</mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dahl</surname><given-names>D</given-names></string-name>, <string-name><surname>Onishi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Norwood</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial</article-title>. <source>JAMA</source><year>2022</year>;<volume>327</volume>:<fpage>534</fpage>–<lpage>545</lpage><pub-id pub-id-type="pmid">35133415</pub-id>
</mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rana</surname><given-names>JS</given-names></string-name>, <string-name><surname>Boekholdt</surname><given-names>SM</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Shah</surname><given-names>PK</given-names></string-name></person-group>. <article-title>The role of non-HDL cholesterol in risk stratification for coronary artery disease</article-title>. <source>Curr Atheroscler Rep</source><year>2012</year>;<volume>14</volume>:<fpage>130</fpage>–<lpage>134</lpage><pub-id pub-id-type="pmid">22203405</pub-id>
</mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wing</surname><given-names>RR</given-names></string-name>, <string-name><surname>Lang</surname><given-names>W</given-names></string-name>, <string-name><surname>Wadden</surname><given-names>TA</given-names></string-name>, <etal/>.; <collab>Look AHEAD Research Group</collab></person-group>. <article-title>Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes</article-title>. <source>Diabetes Care</source><year>2011</year>;<volume>34</volume>:<fpage>1481</fpage>–<lpage>1486</lpage><pub-id pub-id-type="pmid">21593294</pub-id>
</mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Promrat</surname><given-names>K</given-names></string-name>, <string-name><surname>Kleiner</surname><given-names>DE</given-names></string-name>, <string-name><surname>Niemeier</surname><given-names>HM</given-names></string-name>, <etal/></person-group>. <article-title>Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis</article-title>. <source>Hepatology</source><year>2010</year>;<volume>51</volume>:<fpage>121</fpage>–<lpage>129</lpage><pub-id pub-id-type="pmid">19827166</pub-id>
</mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryan</surname><given-names>DH</given-names></string-name>, <string-name><surname>Yockey</surname><given-names>SR</given-names></string-name></person-group>. <article-title>Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over</article-title>. <source>Curr Obes Rep</source><year>2017</year>;<volume>6</volume>:<fpage>187</fpage>–<lpage>194</lpage><pub-id pub-id-type="pmid">28455679</pub-id>
</mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sattar</surname><given-names>N</given-names></string-name>, <string-name><surname>Deanfield</surname><given-names>J</given-names></string-name>, <string-name><surname>Delles</surname><given-names>C</given-names></string-name></person-group>. <article-title>Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes?</article-title><source>Cardiovasc Res</source>. <comment>23 January 2023 [Epub ahead of print]. DOI: </comment><pub-id pub-id-type="doi">10.1093/cvr/cvac186</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lean</surname><given-names>ME</given-names></string-name>, <string-name><surname>Leslie</surname><given-names>WS</given-names></string-name>, <string-name><surname>Barnes</surname><given-names>AC</given-names></string-name>, <etal/></person-group>. <article-title>Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial</article-title>. <source>Lancet</source><year>2018</year>;<volume>391</volume>:<fpage>541</fpage>–<lpage>551</lpage><pub-id pub-id-type="pmid">29221645</pub-id>
</mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>A</given-names></string-name>, <string-name><surname>Morley</surname><given-names>JE</given-names></string-name></person-group>. <article-title>Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes</article-title>. <source>Obes Res</source><year>1998</year>;<volume>6</volume>:<fpage>47</fpage>–<lpage>53</lpage><pub-id pub-id-type="pmid">9526970</pub-id>
</mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mäkimattila</surname><given-names>S</given-names></string-name>, <string-name><surname>Nikkilä</surname><given-names>K</given-names></string-name>, <string-name><surname>Yki-Järvinen</surname><given-names>H</given-names></string-name></person-group>. <article-title>Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus</article-title>. <source>Diabetologia</source><year>1999</year>;<volume>42</volume>:<fpage>406</fpage>–<lpage>412</lpage><pub-id pub-id-type="pmid">10230643</pub-id>
</mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aliakbarian</surname><given-names>H</given-names></string-name>, <string-name><surname>Bhutta</surname><given-names>HY</given-names></string-name>, <string-name><surname>Heshmati</surname><given-names>K</given-names></string-name>, <string-name><surname>Unes Kunju</surname><given-names>S</given-names></string-name>, <string-name><surname>Sheu</surname><given-names>EG</given-names></string-name>, <string-name><surname>Tavakkoli</surname><given-names>A</given-names></string-name></person-group>. <article-title>Pre-operative predictors of weight loss and weight regain following Roux-en-Y gastric bypass surgery: a prospective human study</article-title>. <source>Obes Surg</source><year>2020</year>;<volume>30</volume>:<fpage>4852</fpage>–<lpage>4859</lpage><pub-id pub-id-type="pmid">32748203</pub-id>
</mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dent</surname><given-names>R</given-names></string-name>, <string-name><surname>McPherson</surname><given-names>R</given-names></string-name>, <string-name><surname>Harper</surname><given-names>ME</given-names></string-name></person-group>. <article-title>Factors affecting weight loss variability in obesity</article-title>. <source>Metabolism</source><year>2020</year>;<volume>113</volume>:<fpage>154388</fpage><pub-id pub-id-type="pmid">33035570</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schorr</surname><given-names>M</given-names></string-name>, <string-name><surname>Dichtel</surname><given-names>LE</given-names></string-name>, <string-name><surname>Gerweck</surname><given-names>AV</given-names></string-name>, <etal/></person-group>. <article-title>Sex differences in body composition and association with cardiometabolic risk</article-title>. <source>Biol Sex Differ</source><year>2018</year>;<volume>9</volume>:<fpage>28</fpage><pub-id pub-id-type="pmid">29950175</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DeSouza</surname><given-names>C</given-names></string-name>, <string-name><surname>Cariou</surname><given-names>B</given-names></string-name>, <string-name><surname>Garg</surname><given-names>S</given-names></string-name>, <string-name><surname>Lausvig</surname><given-names>N</given-names></string-name>, <string-name><surname>Navarria</surname><given-names>A</given-names></string-name>, <string-name><surname>Fonseca</surname><given-names>V</given-names></string-name></person-group>. <article-title>Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials</article-title>. <source>J Clin Endocrinol Metab</source><year>2020</year>;<volume>105</volume>:<fpage>dgz072</fpage><pub-id pub-id-type="pmid">31769496</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wood</surname><given-names>MH</given-names></string-name>, <string-name><surname>Carlin</surname><given-names>AM</given-names></string-name>, <string-name><surname>Ghaferi</surname><given-names>AA</given-names></string-name>, <etal/></person-group>. <article-title>Association of race with bariatric surgery outcomes</article-title>. <source>JAMA Surg</source><year>2019</year>;<volume>154</volume>:<fpage>e190029</fpage><pub-id pub-id-type="pmid">30840063</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Samaan</surname><given-names>JS</given-names></string-name>, <string-name><surname>Abboud</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Racial disparities in bariatric surgery postoperative weight loss and patient satisfaction</article-title>. <source>Am J Surg</source><year>2022</year>;<volume>223</volume>:<fpage>969</fpage>–<lpage>974</lpage><pub-id pub-id-type="pmid">34583849</pub-id>
</mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parri</surname><given-names>A</given-names></string-name>, <string-name><surname>Benaiges</surname><given-names>D</given-names></string-name>, <string-name><surname>Schröder</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Preoperative predictors of weight loss at 4 years following bariatric surgery</article-title>. <source>Nutr Clin Pract</source><year>2015</year>;<volume>30</volume>:<fpage>420</fpage>–<lpage>424</lpage><pub-id pub-id-type="pmid">25631913</pub-id>
</mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Funk</surname><given-names>LM</given-names></string-name>, <string-name><surname>Grubber</surname><given-names>JM</given-names></string-name>, <string-name><surname>McVay</surname><given-names>MA</given-names></string-name>, <string-name><surname>Olsen</surname><given-names>MK</given-names></string-name>, <string-name><surname>Yancy</surname><given-names>WS</given-names></string-name>, <string-name><surname>Voils</surname><given-names>CI</given-names></string-name></person-group>. <article-title>Patient predictors of weight loss following a behavioral weight management intervention among US Veterans with severe obesity</article-title>. <source>Eat Weight Disord</source><year>2018</year>;<volume>23</volume>:<fpage>587</fpage>–<lpage>595</lpage><pub-id pub-id-type="pmid">28853051</pub-id>
</mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kotronen</surname><given-names>A</given-names></string-name>, <string-name><surname>Juurinen</surname><given-names>L</given-names></string-name>, <string-name><surname>Hakkarainen</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects</article-title>. <source>Diabetes Care</source><year>2008</year>;<volume>31</volume>:<fpage>165</fpage>–<lpage>169</lpage><pub-id pub-id-type="pmid">17934148</pub-id>
</mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karlsen</surname><given-names>TI</given-names></string-name>, <string-name><surname>Søhagen</surname><given-names>M</given-names></string-name>, <string-name><surname>Hjelmesæth</surname><given-names>J</given-names></string-name></person-group>. <article-title>Predictors of weight loss after an intensive lifestyle intervention program in obese patients: a 1-year prospective cohort study</article-title>. <source>Health Qual Life Outcomes</source><year>2013</year>;<volume>11</volume>:<fpage>165</fpage><pub-id pub-id-type="pmid">24090083</pub-id></mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patel</surname><given-names>H</given-names></string-name>, <string-name><surname>Khunti</surname><given-names>K</given-names></string-name>, <string-name><surname>Rodbard</surname><given-names>HW</given-names></string-name>, <etal/></person-group>. <article-title>Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials</article-title>. <source>Diabetes Obes Metab</source>. <comment>18 October 2023 [Epub ahead of print]. DOI: </comment><pub-id pub-id-type="doi">10.1111/dom.15333</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
